0001104659-24-070419.txt : 20240611 0001104659-24-070419.hdr.sgml : 20240611 20240611163021 ACCESSION NUMBER: 0001104659-24-070419 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240607 FILED AS OF DATE: 20240611 DATE AS OF CHANGE: 20240611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PATEL DINESH V PH D CENTRAL INDEX KEY: 0001120477 ORGANIZATION NAME: STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37852 FILM NUMBER: 241036222 MAIL ADDRESS: STREET 1: C/O PROTAGONIST THERAPEUTICS, INC. STREET 2: 521 COTTONWOOD DRIVE, SUITE 100 CITY: MILPITAS STATE: CA ZIP: 95035 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protagonist Therapeutics, Inc CENTRAL INDEX KEY: 0001377121 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980505495 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 BUSINESS PHONE: (510) 474-0170 MAIL ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Therapeutics Inc DATE OF NAME CHANGE: 20130605 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Inc DATE OF NAME CHANGE: 20061002 4 1 tm2416932-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-06-07 0 0001377121 Protagonist Therapeutics, Inc PTGX 0001120477 PATEL DINESH V PH D C/O PROTAGONIST THERAPEUTICS, INC. 7707 GATEWAY BLVD., SUITE 140 NEWARK CA 94560-1160 1 1 0 0 President and CEO 1 Common Stock 2024-06-07 4 S 0 35000 35.19 D 515415 D Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2023. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $35.00 to $35.53. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Includes an aggregate of 825 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2024. /s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D. 2024-06-11